Iradimed Co (IRMD) - Total Liabilities

Latest as of March 2026: $15.88 Million USD

Based on the latest financial reports, Iradimed Co (IRMD) has total liabilities worth $15.88 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Iradimed Co - Total Liabilities Trend (2012–2025)

This chart illustrates how Iradimed Co's total liabilities have evolved over time, based on quarterly financial data. See IRMD working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Iradimed Co Competitors by Total Liabilities

The table below lists competitors of Iradimed Co ranked by their total liabilities.

Company Country Total Liabilities
Suzhou Jinfu New Material Co
SHE:300128
China CN¥3.09 Billion
Weibo Corp
NASDAQ:WB
USA $2.96 Billion
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
China CN¥5.10 Billion
Waypoint REIT
AU:WPR
Australia AU$986.40 Million
Atresmedia Corporación de Medios de Comunicación S.A.
MC:A3M
Spain €745.49 Million
Neuren Pharmaceuticals Ltd
AU:NEU
Australia AU$7.98 Million
Gibraltar Industries Inc
NASDAQ:ROCK
USA $1.91 Billion
Taboola
NASDAQ:TBLA
USA $599.79 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Iradimed Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Iradimed Co.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 7.13 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.16 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.14 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Iradimed Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Iradimed Co (2012–2025)

The table below shows the annual total liabilities of Iradimed Co from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 $14.16 Million +23.04%
2024-12-31 $11.51 Million -44.51%
2023-12-31 $20.74 Million +75.12%
2022-12-31 $11.84 Million +10.58%
2021-12-31 $10.71 Million +10.59%
2020-12-31 $9.68 Million -13.59%
2019-12-31 $11.20 Million +72.47%
2018-12-31 $6.50 Million +6.82%
2017-12-31 $6.08 Million +14.63%
2016-12-31 $5.31 Million +60.23%
2015-12-31 $3.31 Million +36.88%
2014-12-31 $2.42 Million +54.66%
2013-12-31 $1.56 Million -32.99%
2012-12-31 $2.33 Million --

About Iradimed Co

NASDAQ:IRMD USA Medical Devices
Market Cap
$1.16 Billion
Market Cap Rank
#8417 Global
#2379 in USA
Share Price
$91.09
Change (1 day)
-0.82%
52-Week Range
$56.19 - $105.15
All Time High
$105.15
About

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs moni… Read more